Lumos Pharma Email Format
Biotechnology ResearchTexas, United States11-50 Employees
Lumos Pharma is a clinical-stage biotechnology company based in Austin, Texas, focused on developing therapies for rare diseases. Its lead candidate, LUM-201, is an oral growth hormone–stimulating therapy being developed for pediatric growth hormone deficiency, with the aim of offering an alternative to long-term injections. The firm emphasizes a time- and cost-efficient development path to deliver safe and effective treatments to patients. In addition to LUM-201, Lumos Pharma seeks strategic partnerships to broaden its portfolio by identifying, acquiring, or licensing novel rare-disease programs for development and commercialization. A 2024 development noted by the company includes presenting new analyses from the OraGrowtH212 Phase 2 trial at ENDO 2024.